Synergistic Effect of Ketamine and Buprenorphine Observed in the Treatment of Buprenorphine Precipitated Opioid Withdrawal in a Patient With Fentanyl Use

Background Optimal treatment of buprenorphine precipitated opioid withdrawal (BPOW) is unclear. Full agonist treatment of BPOW is limited by buprenorphine’s high-affinity blockade at mu-opioid receptors (μORs). Buprenorphine’s partial agonism (low intrinsic efficacy) at μORs can limit the effectiveness of even massive doses once BPOW has begun. Adjunct medications, such as clonidine, are rarely effective in severe BPOW. Ketamine is an N-methyl-D-aspartate receptor antagonist with a potentially ideal pharmacologic profile for treatment of BPOW. Ketamine reduces opioid withdrawal symptoms independently of direct μOR binding, synergistically potentiates the effectiveness of buprenorphine μOR signaling, reverses (resensitizes) fentanyl induced μOR receptor desensitization, and inhibits descending pathways of hyperalgesia and central sensitization. Ketamine’s rapid antidepressant effects potentially address depressive symptoms and subjective distress that often accompanies BPOW. Ketamine is inexpensive, safe, and available in emergency departments. To date, neither ketamine as treatment for BPOW nor to support uncomplicated buprenorphine induction has been described. Case Description We report a case of an illicit fentanyl-using OUD patient who experienced severe BPOW during an outpatient low-dose cross taper buprenorphine induction (ie, “microdose”). The BPOW was successfully treated in the emergency department with a combination of ketamine (0.6 mg/kg intravenous over 1 hour) combined with high-dose buprenorphine (16 mg sublingual single dose); 3 days later he was administered a month-long dose of extended-release subcutaneous buprenorphine which was repeated monthly (300 mg). At 90 days the patient remained in treatment and reported continuous abstinence from fentanyl use. Conclusions This single case observation raises important questions about the potential therapeutic role of ketamine as a treatment for BPOW. BPOW is an important clinical problem for which there is currently only limited guidance and no universally accepted approach. Prospective study comparing the effectiveness of differing pharmacologic approaches to treat BPOW is urgently needed.

[1]  S. Shoptaw,et al.  Rapid Adoption of Low-Threshold Buprenorphine Treatment at California Emergency Departments Participating in the CA Bridge Program. , 2021, Annals of emergency medicine.

[2]  J. Dziura,et al.  High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder , 2021, JAMA network open.

[3]  M. Kiyokawa,et al.  A case of buprenorphine-precipitated withdrawal managed with high-dose buprenorphine. , 2021, Family practice.

[4]  N. Volkow The epidemic of fentanyl misuse and overdoses: challenges and strategies , 2021, World psychiatry : official journal of the World Psychiatric Association.

[5]  M. Sofuoglu,et al.  The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder , 2021, Clinical Drug Investigation.

[6]  B. Murnion,et al.  Recurrent Takotsubo Cardiomyopathy Associated with Opioid Withdrawal During Buprenorphine Induction , 2021, Cardiovascular Toxicology.

[7]  Avinash Hosanagar,et al.  Ketamine's rapid antisuicidal effects are not attenuated by Buprenorphine. , 2020, Journal of affective disorders.

[8]  G. Oyler,et al.  Protracted renal clearance of fentanyl in persons with opioid use disorder. , 2020, Drug and alcohol dependence.

[9]  E. Strain,et al.  Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone. , 2020, The American journal on addictions.

[10]  Lewis S. Nelson,et al.  Managing Opioid Withdrawal in the Emergency Department With Buprenorphine. , 2019, Annals of emergency medicine.

[11]  G. Bigelow,et al.  Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals , 2019, Anesthesiology.

[12]  S. Worth,et al.  Opioid Use Disorder , 2018, North Carolina Medical Journal.

[13]  T. S. Sathyanarayana Rao,et al.  A possible role for ketamine in suicide prevention in emergency and mainstream psychiatry , 2017, Indian journal of psychiatry.

[14]  G. Bertschy,et al.  Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: a case report , 2016, BMC Psychiatry.

[15]  B. Frazee,et al.  The first 500: initial experience with widespread use of low-dose ketamine for acute pain management in the ED. , 2015, The American journal of emergency medicine.

[16]  M. Greenwald,et al.  Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. , 2014, Drug and alcohol dependence.

[17]  M. Stone,et al.  Emerging applications of low-dose ketamine for pain management in the ED. , 2013, The American journal of emergency medicine.

[18]  J. Quinlan The use of a subanesthetic infusion of intravenous ketamine to allow withdrawal of medically prescribed opioids in people with chronic pain, opioid tolerance and hyperalgesia: outcome at 6 months. , 2012, Pain medicine.

[19]  L. Devi,et al.  Potentiation of μ‐opioid receptor‐mediated signaling by ketamine , 2011, Journal of neurochemistry.

[20]  S. Vosylius,et al.  Effects of ketamine on precipitated opiate withdrawal. , 2006, Medicina.

[21]  R. Strassman,et al.  Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. , 2002, Journal of substance abuse treatment.